/SCOL.ST
SCOL.ST Stock - Scandion Oncology A/S
Healthcare|BiotechnologySTO
$0.00-39.71%
$0.00 (-39.71%) • Jul 11
44
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.46
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SCOL.ST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.00 – $0.00
TARGET (TP)$0.00
STOP LOSS$0.00
RISK/REWARD1:-1.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.86
52W High$0.18
52W Low$0.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-323,523 | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-63,091,612 | $-45,357,000 | $-80,166,000 | $-55,367,000 | $-22,888,000 |
| Net Income | $-56,207,163 | $-39,204,000 | $-76,700,000 | $-51,705,000 | $-16,269,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.24 | $-0.96 | $-1.79 | $-1.61 | $-0.51 |
Company Overview
Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of chemotherapy resistance. Its lead product candidate includes the SCO-101, an oral compound that is in clinical Phase Ib and Phase II studies in cancer patients. The company's other product candidate is SCO-201, which is in preclinical trial for the treatment of solid tumors. Scandion Oncology A/S was founded in 2017 and is headquartered in Copenhagen, Denmark.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
SCOL.STBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.10
Q1 2025
EPS Surprise History
Q1 23
No data
Q2 23
No data
Q3 23
No data
Q4 23
No data
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q1 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 20, 2026 | — | — | — | — |
Q1 2026 | Mar 10, 2026 | — | — | — | — |
Q4 2025 | Nov 11, 2025 | — | — | — | — |
Q3 2025 | Aug 28, 2025 | — | — | — | — |
Q2 2025 | May 22, 2025 | — | — | — | — |
Q1 2025 | Mar 12, 2025 | — | $-0.10 | — | — |
Q4 2024 | Nov 11, 2024 | — | — | — | — |
Q3 2024 | Aug 29, 2024 | — | $-0.05 | — | — |
Q2 2024 | May 22, 2024 | — | $-0.30 | — | — |
Q1 2024 | Feb 28, 2024 | — | $-0.40 | — | — |
Q4 2023 | Nov 22, 2023 | — | $-0.39 | — | — |
Q3 2023 | Aug 23, 2023 | — | $-0.35 | — | — |
Q2 2023 | May 26, 2023 | — | $-0.35 | — | — |
Q1 2023 | Feb 22, 2023 | — | $-0.48 | — | — |
Q4 2022 | Nov 16, 2022 | — | $-0.97 | — | — |
Q3 2022 | Aug 25, 2022 | — | $-1.04 | — | — |
Q2 2022 | May 19, 2022 | — | $-0.56 | — | — |
Q1 2022 | Feb 17, 2022 | — | $-0.51 | — | — |
Q4 2021 | Nov 18, 2021 | — | $-0.65 | — | — |
Q3 2021 | Aug 19, 2021 | — | $-0.53 | — | — |
Latest News
Loading news...
Frequently Asked Questions about SCOL.ST
What is SCOL.ST's current stock price?
Scandion Oncology A/S (SCOL.ST) is currently trading at $0.00 per share. The stock has moved -39.71% today.
What is the analyst price target for SCOL.ST?
No analyst price targets are currently available for this stock.
What sector is Scandion Oncology A/S in?
Scandion Oncology A/S operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the STO exchange.
What is SCOL.ST's market cap?
Scandion Oncology A/S has a market capitalization of $0.00 billion, making it a small-cap company.
Does SCOL.ST pay dividends?
No, Scandion Oncology A/S does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorEXPRS2.ST
ExpreS2ion Biotech Holding AB (publ)
$16.92
Mkt Cap: $0.0B
FLUO.ST
FluoGuide A/S
$36.20
Mkt Cap: $0.5B
HNSA.ST
Hansa Biopharma AB (publ)
$31.24
Mkt Cap: $2.6B
ONCO.ST
Oncopeptides AB (publ)
$4.57
Mkt Cap: $1.0B
SANION.ST
Saniona AB (publ)
$20.60
Mkt Cap: $2.8B
Explore stocks similar to SCOL.ST for comparison